Defining the Immune Landscape of Neuroendocrine Tumors – Towards Rational Combination Therapy
Researcher: Professor Tim Meyer, MD, PhD Location: UCL Cancer Institute - University College London Year: 2015 Status: Finished Grant Duration: 1 year
Leave it blank
To characterize the immune microenvironment of neuroendocrine tumors and understand how it responds to therapy and to develop the rationale for combination immunotherapy for patients with neuroendocrine tumors.
The status of the immune ‘landscape’ of neuroendocrine tumors before therapy and after modulation by therapy is unknown. The proposed study will analyse reactive T cell subsets including characterization of the regulatory factors limiting effective immune-mediated tumour elimination. This will inform the development of a truly personalized medicine approach capable of inducing tumour regression and durable disease control.
In this proposal we bring together a team of NET specialists from one of the largest NET Centres in Europe, and the first ENETS Centre of Excellence, with internationally recognised leaders in the field of immunotherapy and tumour genetics, in order to systematically evaluate the potential for immunotherapy to bring benefit to patients with NET.
To characterize the immune microenvironment of neuroendocrine tumors and understand how it responds to therapy
To develop the rationale for combination immunotherapy for patients with neuroendocrine tumors.
Currently, surgery is the only treatment that cures patients with neuroendocrine cancer but this is not feasible for the majority of patients because they present with inoperable metastatic disease. Medical therapies, at best, slow the disease and new approaches are needed. Immunotherapy, which releases the brakes from the patient’s immune system and allows immune cells to attack the cancer is resulting in long term survival in other tumour types. These new approaches have not been explored in NETs and our project aims to provide a rationale for their clinical evaluation in the hope that patients with NET may also benefit from the revolution in immunotherapy.
NET Research Foundation
321 Columbus Avenue, Suite 5R
Boston MA 02116